Clinical Trial Update: Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Favrille vaccine therapy with sargramostim versus placebo with sargramostim after rituximab in non-Hodgkin lymphoma has been terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Favrille vaccine
• Rituximab (rituximab)
• sargramostim (sargramostim)

Snippet

Sponsor: Favrille | Conditions: Lymphoma | Phase 3 | Status: TERMINATED